Efficacy and safety of praziquantel against light infections of Opisthorchis viverrini : a randomised parallel single blind dose-ranging trial | Zendy

Somphou Sayasone | Zendy; Isabel Meister | Zendy; Jason R. Andrews | Zendy; Peter Odermatt | Zendy; Youthanavanh Vonghachack | Zendy; Syda Xayavong | Zendy; Kanpaseuth Senggnam | Zendy; Khampheng Phongluxa | Zendy; Jan Hattendorf | Zendy; Isaac I. Bogoch | Zendy; Jennifer Keiser | Zendy

Open Access

Efficacy and safety of praziquantel against light infections of Opisthorchis viverrini : a randomised parallel single blind dose-ranging trial

Author(s) -

Somphou Sayasone,

Isabel Meister,

Jason R. Andrews,

Peter Odermatt,

Youthanavanh Vonghachack,

Syda Xayavong,

Kanpaseuth Senggnam,

Khampheng Phongluxa,

Jan Hattendorf,

Isaac I. Bogoch,

Jennifer Keiser

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw785

Subject(s) - opisthorchis viverrini , medicine , praziquantel , adverse effect , dose ranging study , regimen , opisthorchiasis , chemotherapy , gastroenterology , placebo , surgery , liver fluke , immunology , schistosomiasis , pathology , double blind , alternative medicine , helminths

The liver fluke Opisthorchis viverrini, highly prevalent in Southeast Asia, is an important public health burden, including a risk factor for developing an aggressive bile duct cancer, cholangiocarcinoma, in chronically infected patients. Praziquantel, administered at a single 40 mg/kg dose in preventive chemotherapy programs and 3 × 25 mg/kg for individual treatment, is the drug of choice, yet information on the nature of the dose-response relationship is lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research